Summer Sale
50% off Premium Yearly
NYSE:LLY
Eli Lilly & Co. (LLY)
Financials 
Technical Analysis 
Aug 25, 2026, 12:00 amThis summary was created by AI, based on 29 opinions in the last 12 months.
Eli Lilly & Co. (LLY) is recognized as a leading player in the healthcare industry, particularly in the GLP-1 drug market, which has driven significant stock performance, up approximately 370% over the past five years. Experts highlight the company’s robust drug pipeline, strong execution, and expansion plans, particularly with the anticipated oral version of its weight-loss drug. Despite these strengths, many analysts warn about current high valuations, suggesting that the stock may be priced to perfection, creating caution around new investments at present levels. While the company has a diversified portfolio beyond GLP-1 drugs, stock performance has recently hit all-time highs, prompting some to advise a strategic wait for pullbacks before making new purchases. Overall, analysts see a positive growth trajectory for Eli Lilly in terms of revenue and earnings, backed by a strong market position and effective management of its drug offerings.
Remarkable momentum, trading like a biotech. Great news today, but the PE is a little rich at 60x.
Joe Terranova
At one point this year was the worse-performing stock. Their weight-loss drug is energizing shareholders, but the government needs to approve it. He urged buying during last month's dip. Eli Lilly also has a promising Alzheimer's drug in the pipeline, so it's no one-trick pony. Shares have rebounded to 2023 highs.
Has done well. Their diabetes drug is effective for weight loss, which is pending approval, but would open a new market. She expects approval. Stock price reflects this approval though. Weight loss is a lucrative market given obesity levels around the world. The PE is too high for her, but may buy on a pullback.
The whole drug industry has been under pressure for the past 30 years and is having more and more trouble coming up with new drugs. R&D costs are increasing so he doesn't like the pharmaceutical industry in general. In response to a question regarding the currency component he doesn't feel it is an issue.
It has outperformed the sector. The technicals are OK but but it is not in a great space. He owns some but would not buy more at this time.
David Burrows
David Fingold
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Alzheimer's drug looks interesting, concerns about side effects. Good cancer drugs. Interesting diabetes and weight loss drug. 45x forward earnings, 20%+ growth rate. Pricey, be cautious. RSI at 79% is overbought. He owns MRK.